References
- Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., and Schneider, R. L., Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care, 23, 1605-1611(2000) https://doi.org/10.2337/diacare.23.11.1605
- Berger, J. and Moller, D. E., The mechanisms of action of PPARs. Ann. Rev. Med., 53, 409-435 (2002) https://doi.org/10.1146/annurev.med.53.082901.104018
- Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Snith, S. A., and Thurlby P. L., [[Omega-(heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994) https://doi.org/10.1021/jm00049a017
- Dahl-Jorgensen, K. and Brinchmann-Hansen, O., Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study. Br. Med.J., 293, 1195-1199 (1986) https://doi.org/10.1136/bmj.293.6556.1195
- Defronzo, R. A., Bonadonna, R. C., and Ferrannini, E., Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318-368 (1992) https://doi.org/10.2337/diacare.15.3.318
- Defronzo, R. A., Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 37, 667-687 (1988) https://doi.org/10.2337/diab.37.6.667
- Desvergne, B. and Wahli, W., Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endcrine Rev., 20, 649-688 (1999) https://doi.org/10.1210/er.20.5.649
- Feldt-Rasmussen, B., Mathisesn, E., and Deckert, T., Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet, 2, 1300-1304 (1986)
- Holman, R. R. and Turner, R. C., Textbook of Diabetes; Pickup, J. C., Williams, G. Eds.; Blackwell Scientofic Publications: London, pp 462-476 (1991)
- Ibrahimi, A., Teboul, L., Gaillard, D., Amir, E. Z., Ailhaud, G., Young, P., Cawthorne, M. A., and Grimardi, P. A., Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol., 46, 1070-1076 (1994)
- Kersten, S., Desvergne, B., and Wahli, W., Roles of PPARs in health and disease. Nature, 405, 421-424 (2000) https://doi.org/10.1038/35013000
- Kletzien, R. F., Clark, S. D., and Ulrich, R. G., Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol., 41, 393-398 (1992)
- Lehmann, J. M., Moorre, L. B., Smith-Oliver,T A, Wilkinson, W. O., Wilson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995) https://doi.org/10.1074/jbc.270.22.12953
-
Martin, G., Schoonjans, K., Staels, B., and Aurex, J.,
$PPAR{\gamma}$ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atheroscrelosis, 137 (Suppl), S75-S80 (1998) https://doi.org/10.1016/S0021-9150(97)00315-8 - Morita, H., Mori, H., and Kobayashi, Y., Process for the production of a thiazolidine derivative. GB 2324089A (1998)
- Ruderman, N. B. and Scheneider, S. H., Diabetes, exercise, and atherosclerosis. Diabetes Care, 15 (Suppl. 4), 1787-1793 (1992) https://doi.org/10.2337/diacare.15.11.1787
- Sohda, T., Momose, Y., Meguro, K., Kawamatsu, Y., Sugiyama, Y., and Ikeda, H., Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones. Arzneim.-Forsch., 40, 37-42 (1990)
- Yoshioka, T., Fujita, T., Kanai, T., Aizawa, Y., Kurumada, T., Hasegawa, K., and Horikoshi, H., Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem., 32,421-428 (1989) https://doi.org/10.1021/jm00122a022